|
1
|
Exarchos KP, Goletsis Y and Fotiadis DI: A
multiscale and multiparametric approach for modeling the
progression of oral cancer. BMC Med Inform Decis Mak. 12:1362012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global Cancer Statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
3
|
Tanaka T, Tanaka M and Tanaka T: Oral
carcinogenesis and oral cancer chemoprevention (review). Patholog
Res Int. 2011:4312462011.PubMed/NCBI
|
|
4
|
Inagi K, Takahashi H, Okamoto M, Nakayama
M, Makoshi T and Nagai H: Treatment effects in patients with
squamous cell carcinoma of the oral cavity. Acta Otolaryngol
(Suppl). 547:25–29. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shingaki S, Takada M, Sasai K, Bibi R,
Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis
on the pattern of failure and survival in oral carcinomas. Am J
Surg. 185:278–284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wise-Draper TM, Draper DJ, Gutkind JS,
Molinolo AA, Wikenheiser-Brokamp KA and Wells SI: Future directions
and treatment strategies for head and neck squamous cell
carcinomas. Transl Res. 160:167–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Russell JS and Colevas AD: The use of
epidermal growth factor receptor monoclonal antibodies in squamous
cell carcinoma of the head and neck. Chemother Res Pract.
2012:7615182012.PubMed/NCBI
|
|
8
|
Vincenzi B, Zoccoli A, Pantano F, Venditti
O and Galluzzo S: Cetuximab: from bench to bedside. Curr Cancer
Drug Targets. 10:80–95. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peng D, Fan Z, Lu Y, DeBlasio T, Scher H
and Mendelsohn J: Anti-epidermal growth factor receptor monoclonal
antibody 225 upregulates p27KIP1 and induces G1 arrest
in prostatic cancer cell line DU145. Cancer Res. 56:3666–3669.
1996.PubMed/NCBI
|
|
10
|
Wani MC, Taylor HL, Wall ME, Coggon P and
McPhail AT: Plant antitumor agents. VI The isolation and structure
of taxol, a novel antileukemic and antitumor agent from Taxus
brevifolia. J Am Chem Soc. 93:2325–2327. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rowinsky EK, Donehower RC, Jones RJ and
Tucker RW: Microtubule changes and cytotoxicity in leukemic cell
lines treated with taxol. Cancer Res. 48:4093–4100. 1988.PubMed/NCBI
|
|
12
|
Schiff PB, Fant J and Horwitz SB:
Promotion of microtubule assembly in vitro by taxol. Nature.
277:665–667. 1979. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Langer CJ, Lee JW, Patel UA, Shin DM,
Argiris AE, Quon H, Ridge JA and Forastiere AA: Concurrent
radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable,
locally advanced (LA) squamous cell carcinoma of the head and neck
(SCCHN). J Clin Oncol. 26:20(abst 6006). 2008.PubMed/NCBI
|
|
14
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J,
Youssoufian H, Rowinsky EK and Ang KK: Radiotherapy plus cetuximab
for locoregionally advanced head and neck cancer: 5-year survival
data from a phase 3 randomised trial, and relation between
cetuximab-induced rash and survival. Lancet Oncol. 11:21–28.
2010.PubMed/NCBI
|
|
15
|
Sosa AE, Grau JJ, Feliz L, Pereira V,
Alcaraz D, Muñoz-García C and Caballero M: Outcome of patients
treated with palliative weekly paclitaxel plus cetuximab in
recurrent head and neck cancer after failure of platinum-based
therapy. Eur Arch Otorhinolaryngol. 271:373–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiménez B, Trigo JM, Pajares BI, Sáez MI,
Quero C, Navarro V, Llácer C, Medina L, Rueda A and Alba E:
Efficacy and safety of weekly paclitaxel combined with cetuximab in
the treatment of pretreated recurrent/metastatic head and neck
cancer patients. Oral Oncol. 49:182–185. 2013.PubMed/NCBI
|
|
17
|
Hitt R, Irigoyen A, Cortes-Funes H, Grau
JJ, García-Sáenz JA and Cruz-Hernandez JJ; Spanish Head and Neck
Cancer Cooperative Group (TTCC). Phase II study of the combination
of cetuximab and weekly paclitaxel in the first-line treatment of
patients with recurrent and/or metastatic squamous cell carcinoma
of head and neck. Ann Oncol. 23:1016–1022. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong YN, Litwin S, Vaughn D, Cohen S,
Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H and Hudes G:
Phase II trial of cetuximab with or without paclitaxel in patients
with advanced urothelial tract carcinoma. J Clin Oncol.
30:3545–3551. 2012. View Article : Google Scholar
|
|
19
|
Mecca C, Ponzetti A, Caliendo V, Ciuffreda
L and Lista P: Complete response of metastatic cutaneous squamous
cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol.
22:758–761. 2012.PubMed/NCBI
|
|
20
|
Beg AA, Sha WC, Bronson RT, Ghosh S and
Baltimore D: Embryonic lethality and liver degeneration in mice
lacking the RelA component of NF-κB. Nature. 376:167–170.
1995.PubMed/NCBI
|
|
21
|
Cai Z, Korner M, Tarantino N and Chouaib
S: IκB-α overexpression in human breast carcinoma MCF7 cells
inhibits nuclear factor-κB activation but not tumor necrosis
factor-α-induced apoptosis. J Biol Chem. 272:96–101. 1997.
|
|
22
|
Bargou RC, Emmerich F, Krappmann D,
Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A,
Scheidereit C and Dorken B: Constitutive nuclear factor-kappa
B-RelA activation is required for proliferation and survival of
Hodgkin’s disease tumor cells. J Clin Invest. 100:2961–2969.
1997.PubMed/NCBI
|
|
23
|
Sovak MA, Bellas RE, Kim DW, Zanieski GJ,
Rogers AE, Traish AM and Sonenshein GE: Aberrant nuclear
factor-κB/Rel expression and the pathogenesis of breast cancer. J
Clin Invest. 100:2952–2960. 1997.
|
|
24
|
Shen HM and Tergaonkar V: NFkappaB
signaling in carcinogenesis and as a potential molecular target for
cancer therapy (review). Apoptosis. 14:348–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beg AA and Baldwin AS Jr: The IκB
proteins: multifunctional regulators of Rel/NF-κB transcription
factors. Genes Dev. 7:2064–2070. 1993.
|
|
26
|
Duffey D, Chen Z, Dong G, Ondrey FG, Wolf
JF, Brown K, Siebenlist U and Van Waes C: Expression of a
dominant-negative mutant inhibitor-κBα of nuclear factor-κB in
human head and neck squamous cell carcinoma inhibits survival,
proinflammatory cytokine expression, and tumor growth in vivo.
Cancer Res. 59:3468–3474. 1999.
|
|
27
|
Wang CY, Mayo MW and Baldwin AS Jr: TNF-
and cancer therapy-induced apoptosis: Potentiation by inhibition of
NF-κB. Science. 274:784–787. 1996.PubMed/NCBI
|
|
28
|
Wang CY, Mayo MW, Korneluk RG, Goeddel DV
and Baldwin AS Jr: NF-κB antiapoptosis: Induction of TRAF1 and
TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281:1680–1683. 1998.
|
|
29
|
Das KC and White CW: Activation of NF-κB
by antineoplastic agents. J Biol Chem. 272:14914–14920. 1997.
|
|
30
|
Spencer W, Kwon H, Crépieux P, Leclerc N,
Lin R and Hiscott J: Taxol selectively blocks microtubule dependent
NF-κB activation by phorbol ester via inhibition of IκB-α
phosphorylation and degradation. Oncogene. 18:495–505.
1999.PubMed/NCBI
|
|
31
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C,
Schueler A, Amellal N and Hitt R: Platinum-based chemotherapy plus
cetuximab in head and neck cancer. N Engl J Med. 359:1116–1127.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mesia R, Rivera F, Kawecki A, Rottey S,
Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski
P, Delord JP, Bokemeyer C, Curran D, Gross A and Vermorken JB:
Quality of life of patients receiving platinum-based chemotherapy
plus cetuximab first line for recurrent and/or metastatic squamous
cell carcinoma of the head and neck. Ann Oncol. 21:1967–1973. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leon X, Hitt R, Constenla M, Rocca A,
Stupp R, Kovács AF, Amellal N, Bessa EH and Bourhis J: A
retrospective analysis of the outcome of patients with recurrent
and/or metastatic squamous cell carcinoma of the head and neck
refractory to a platinum-based chemotherapy. Clin Oncol (R Coll
Radiol). 17:418–424. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Janmaat ML, Kruyt FA, Rodriguez JA and
Giaccone G: Response to epidermal growth factor receptor inhibitors
in nonsmall cell lung cancer cells: limited antiproliferative
effects and absence of apoptosis associated with persistent
activity of extracellular signal-regulated kinase or Akt kinase
pathways. Clin Cancer Res. 9:2316–2326. 2003.
|
